Last updated on April 2020

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: miller-dieker syndrome | MYELODYSPLASTIC SYNDROME
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Age 18
  • CMML diagnosis according to WHO criteria Stable excess in blood monocytes, > 1 G/L Lack of bcr-abl rearrangement (or Philadelphia chromosome) Bone marrow blast cells < 20% Dysplasia of at least one lineage or clonality marker or blood monocytosis during more than 3 months w/o other explanation Blood and marrow smears will be reviewed at each country's level, but morphologist meetings at the 3 country level are planned for better harmonization and review of difficult cases
  • WBC 13 G/L Measured on two successive CBC at least two weeks apart, outside of a context of infection.
  • Either D1 or D2

D1: At least two of the following criteria, reviewed at each country's level: (modified from Wattel et al. Blood 1996) Marrow blasts >= 5 % Clonal cytogenetic abnormality (other than t(5;12) (q33; p13) and isolated loss of Y chromosome ) Anemia (Hb < 10 g/dL) ANC > 16 G/l (in absence of infection) Thrombocytopenia (platelet count < 100 G/L) Splenomegaly > 5 cm below costal margin (spleen size should also be measured by an imaging technique)


D2: Extramedullary involvement: Including documented cutaneous, pleural or pericardial effusion.

  • No prior treatment (except supportive care, or ESA, or short term (< 6 weeks) HY in patients presenting with high WBC counts)
  • Performance status 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale.
  • Adequate organ function including the following Hepatic : total bilirubin < 1.5 times upper limit of normal (ULN) (except moderate unconjugated hyperbilirubinemia due to intra medullary hemolysis or Gilbert syndrome) , alanine transaminase (ALT) and aspartate transaminase (AST) < 3xULN Renal : serum creatinine < 2 x ULN
  • Signed Informed consent
  • Negative pregnancy and adequate contraception (including in male patients wishing to father) if relevant.

Exclusion Criteria:

  • Myeloproliferative / myelodysplastic syndrome other than CMML
  • CMML with t(5 ;12) or PDGFBR rearrangement that may receive imatinib
  • Patients eligible for allogeneic bone marrow transplantation with an identified donor
  • Pregnant or breastfeeding
  • Performance status > 2 on the ECOG Scale.
  • Serious concomitant systemic disorder, including active bacterial, fungal or viral infection that in the opinion of the investigator would compromise the safety of the patient and/or his/her ability to complete the study
  • Prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, or other tumors if not active during the last 3 years)

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.